logo
Best money market account rates today, June 16, 2025 (Earn up to 4.41% APY)

Best money market account rates today, June 16, 2025 (Earn up to 4.41% APY)

Yahoo5 hours ago

Find out which banks are offering the top rates. Money market accounts (MMAs) can be a great place to store your cash if you're looking for a relatively high interest rate along with liquidity and flexibility.
Unlike traditional savings accounts, MMAs typically offer better returns, and they may also provide check-writing privileges and debit card access. This makes these accounts ideal for holding long-term savings that you want to grow over time, but can still access when needed for certain purchases or bills.
Even though rates have been falling over the past several months, it's still possible to find money market accounts that pay more than 4% APY.
Here is a look at some of today's best money market account rates:
Interested in earning the best possible interest rate on your savings balance? Here is a look at some of the best savings and money market account rates available today from our verified partners.
This embedded content is not available in your region.
Money market account rates have fluctuated significantly in recent years, largely due to changes in the Federal Reserve's target interest rate.
In the wake of the 2008 financial crisis, for example, interest rates were kept extremely low to stimulate the economy. The Fed slashed the federal funds rate to near zero, which led to very low MMA rates. During this time, money market account rates were typically around 0.10% to 0.50%, with many accounts offering rates on the lower end of that range.
Eventually, the Fed began raising interest rates gradually as the economy improved. This led to higher yields on savings products, including MMAs. However, in 2020, the COVID-19 pandemic led to a brief but sharp recession, and the Fed once again cut its benchmark rate to near zero to combat the economic fallout. This resulted in a sharp decline in MMA rates.
But starting in 2022, the Fed embarked on a series of aggressive interest rate hikes to combat inflation. This led to historically high deposit rates across the board. By late 2023, money market account rates had risen substantially, with many accounts offering 4% or higher. However, the Fed finally began cutting rates in late 2024.
As of 2025, MMA rates remain high by historical standards, though they've begun a downward trajectory following the Fed's most recent rate cuts. Today, online banks and credit unions tend to offer the highest rates.
When comparing money market accounts, it's important to look beyond just the interest rate. Other factors, such as minimum balance requirements, fees, and withdrawal limits, can impact the total value you get from the account.
For example, it's common for money market accounts to require a large minimum balance in order to earn the highest advertised rate — as much as $5,000 or more in some cases. Other accounts may charge monthly maintenance fees that can eat into your interest earnings.
However, there are several MMAs available that offer competitive rates without any balance requirements, fees, or other restrictions. That's why it's important to shop around and compare accounts before making a decision.
Additionally, ensure that the account you choose is insured by the Federal Deposit Insurance Corporation (FDIC) or the National Credit Union Administration (NCUA), which guarantees deposits up to $250,000 per institution, per depositor. Most money market accounts are federally insured, but it's important to double-check in the rare case the financial insitution fails.
Read more: Money market account vs. high-yield savings account: Which is best for you?
The national average interest rate for money market accounts is just 0.64%, according to the FDIC. However, the best money market account rates often pay around 4% to 4.50% APY — similar to the rates offered on high-yield savings accounts.
The amount you will earn on $50,000 in a money market account depends on the annual percentage rate (APY) and the time period you leave the money in the account. For example, if you deposit $50,000 into a money market account that pays 4.5% APY and left it in your account for one year, you'd earn $2,303 in interest.
There are currently no money market accounts that pay 5% APY. However, some high-yield savings accounts from online banks do. You can also check with your local bank or credit union to find out if they offer a 5% APY account that fits your needs.
This embedded content is not available in your region.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

mRNA Vaccine Core Enzyme Market to Reach USD 7 Billion by 2034
mRNA Vaccine Core Enzyme Market to Reach USD 7 Billion by 2034

Yahoo

time37 minutes ago

  • Yahoo

mRNA Vaccine Core Enzyme Market to Reach USD 7 Billion by 2034

mRNA Vaccine Core Enzyme Market Overview 2025-2034 Luton, Bedfordshire, United Kingdom, June 16, 2025 (GLOBE NEWSWIRE) -- The global mRNA vaccine core enzyme market is witnessing unprecedented growth, driven by heightened demand for rapid vaccine development and growing advancements in biotechnology. As of 2024, the market is valued at approximately USD 2.3 billion, with projections indicating it will reach nearly USD 7 billion by 2034, reflecting a CAGR of 13.4% over the forecast period. This growth trajectory is underpinned by expanding applications of mRNA technology across infectious diseases, cancer therapeutics, and personalized medicine, along with increased public and private sector investments. Download PDF Brochure: The COVID-19 pandemic played a transformative role in bringing mRNA vaccine technologies into the spotlight, proving their potential for rapid response and scalable deployment. As governments, pharmaceutical companies, and research institutions pivot towards future pandemic preparedness and broader therapeutic applications, the core enzymes essential for mRNA synthesis and delivery—such as polymerases and lipid nanoparticles—are in increasingly high demand. Market Segmentation Analysis By Product Type The market is segmented into Poly(A) Polymerase, RNA Polymerase, Nudge Enzyme, and Other Enzymes. Among these, Poly(A) Polymerase holds a dominant share due to its essential role in stabilizing synthetic mRNA transcripts for vaccine formulation. Enhanced purification techniques have also improved the quality and reliability of Poly(A) Polymerase, increasing its demand. RNA Polymerase, equally critical, is widely used in transcription processes to synthesize mRNA from DNA templates. It finds applications in both commercial vaccine production and academic research. Nudge Enzymes, although newer to the market, are gaining traction due to their emerging role in improving mRNA stability and delivery efficiency. These innovations signal strong growth prospects, particularly for advanced research and personalized therapies. By Application The therapeutics segment is emerging as a key growth driver within the application spectrum, spurred by research into using mRNA technology for cancer treatment, autoimmune conditions, and rare diseases. Collaborations between biotech startups and large pharmaceutical firms are fostering the development of new therapeutic platforms leveraging mRNA enzymes. In contrast, preventive vaccines remain the cornerstone of the mRNA enzyme market, bolstered by ongoing global vaccination programs and the anticipation of future pandemics. The success of COVID-19 mRNA vaccines has underscored the need for faster, adaptable vaccine platforms. Research and development (R&D) also constitutes a significant market share. A surge in clinical trials and funding for pre-clinical mRNA studies—especially in academic and research institutions—continues to drive enzyme demand, particularly as R&D efforts expand to newer disease areas. By End User Pharmaceutical companies form the largest end-user segment, leveraging their production capacity, regulatory expertise, and global distribution networks to manufacture large volumes of mRNA-based products. These firms rely heavily on high-quality enzymes for consistent vaccine efficacy. Academic and research institutions, while smaller in scale, play a vital role in early-stage innovation and pilot studies. They frequently collaborate with biotech firms to explore novel mRNA applications, thereby fueling demand for research-grade enzymes. Biotech companies, particularly startups focused on gene editing and personalized medicine, represent a fast-growing end-user base. These companies require scalable and customizable enzyme solutions, thereby creating a niche yet dynamic demand profile. By Technology The market is further categorized by technology into In Vitro Transcription, Purification Technologies, and Quality Control and Characterization Technologies. Among these, In Vitro Transcription (IVT) is foundational to mRNA synthesis. Continued optimization has enhanced both yield and cost-efficiency, making IVT indispensable for vaccine production. Purification technologies ensure removal of contaminants and increase product stability. Emerging trends involve automating these processes to minimize human error and improve throughput. Meanwhile, quality control and characterization technologies are becoming increasingly vital due to stringent regulatory requirements. These technologies facilitate consistency, batch reproducibility, and compliance, making them a key area for future investments. By Distribution Channel Distribution of mRNA enzymes occurs through direct sales, online platforms, and third-party distributors. Direct sales remain preferred by pharmaceutical companies for custom orders and quality assurance, ensuring close coordination with enzyme manufacturers. However, online sales are on the rise, particularly among academic institutions and smaller biotech firms looking for convenience and cost savings. The trend reflects a broader shift toward digital procurement models in the life sciences sector. Third-party distributors serve an important role in extending enzyme availability to emerging markets and underserved regions. Their reach and logistical support are critical to ensuring timely supply in areas lacking direct access to manufacturers. Browse full Report - Market Segmentation By Product Type - Poly(A) Polymerase - RNA Polymerase - Nudge Enzyme By Application - Therapeutics - Preventive Vaccines - Research and Development By End-user - Pharmaceutical Companies - Academic and Research Institutions - Biotech Companies By Distribution Channel - Direct Sales - Online Sales - Third-party Distributors By Technology - In Vitro Transcription - Purification technologies - Quality control and characterization technologies By Region - North America - Europe - Asia Pacific - Latin America - Middle East and Africa Regional Insights North America North America leads the global mRNA vaccine core enzyme market, contributing approximately 45% of global revenue in 2024. The U.S. stands at the forefront due to its robust biotech ecosystem, deep investment in R&D, and support from regulatory bodies like the FDA. Strategic collaborations between pharma giants and research institutions further accelerate innovation and commercialization. The region is expected to grow at a CAGR of around 8.5% through 2034. Europe Europe holds a significant market share of around 30%, led by countries like Germany, the UK, and France. Favorable government policies, strong academic research infrastructure, and a growing emphasis on biotechnology are propelling market growth. A CAGR of 7.0% is anticipated through 2034 as EU nations enhance their domestic vaccine capabilities and biotech investments. Asia Pacific Asia Pacific is the fastest-growing region, projected to expand at a CAGR of 10.5% by 2034. Major drivers include rising investments in health infrastructure, expanding pharmaceutical manufacturing hubs in China and India, and increasing public health awareness. However, challenges such as regulatory complexity and uneven infrastructure persist across the region. Latin America and Middle East & Africa Emerging markets like Latin America and Africa are exhibiting strong growth potential, driven by improvements in public health funding and localized vaccine production. Though still nascent, these regions are expected to attract future investment. Infrastructure and regulatory challenges, however, may temper the pace of growth unless addressed through public-private collaboration. Buy Now: Key Competitors Moderna Inc. BioNTech SE Pfizer Inc. CureVac AG Gennova Biopharmaceuticals Zydus Cadila Sanofi AstraZeneca Merck & Co., Inc. Novavax Inc. Regeneron Pharmaceuticals Translate Bio Genexine Inc. AbCellera Biologics Takeda Pharmaceutical Company Limited Recent Market Developments Moderna Inc. expanded its mRNA production facility in Norwood, Massachusetts in August 2023, aiming to scale up production in response to growing global demand. BioNTech SE launched a next-generation mRNA-based influenza vaccine in September 2023, signaling a shift toward seasonal applications beyond COVID-19. CureVac AG announced a strategic partnership in July 2023 with a major pharmaceutical firm to co-develop mRNA therapies, highlighting a trend toward collaboration and shared risk. Zydus Cadila received regulatory approval in India for its mRNA COVID-19 vaccine in October 2023, positioning the country as a significant player in localized mRNA production. Pfizer Inc. acquired a biotech firm specializing in advanced mRNA platforms in November 2023, bolstering its pipeline and reaffirming its commitment to innovation. This report is also available in the following languages : Japanese (mRNAワクチンコア酵素市場), Korean (mRNA 백신 핵심 효소 시장), Chinese (mRNA疫苗核心酶市场), French (Marché des enzymes de base des vaccins à ARNm), German (Markt für mRNA-Impfstoff-Kernenzyme), and Italian (Mercato degli enzimi fondamentali del vaccino mRNA), etc. Request Sample Pages: More Research Finding – Tozinameran Market The global market for Tozinameran, a key COVID-19 mRNA vaccine, is valued at approximately $21 billion. The market is expected to grow significantly, with a projected value of around $45 billion by 2034. This represents a Compound Annual Growth Rate (CAGR) of about 8.1% from 2025 to 2034. mRNA Vaccine and Therapeutics Raw Material Market The global market for mRNA vaccine and therapeutics raw materials is valued at approximately $4.5 billion, driven by the accelerating demand for innovative vaccine solutions and therapeutic modalities. The market is projected to reach around $9.2 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of approximately 8.2% from 2025 to 2034. Non-invasive Vaccine Market The global non-invasive vaccine market is projected to reach a value of approximately $2.5 billion in 2024, driven by advancements in vaccine delivery systems and increasing demand for pain-free immunization methods. During the forecast period from 2025 to 2034, the market is expected to experience significant growth, with an estimated compound annual growth rate (CAGR) of 11.5%. Foot and Mouth Disease FMD Vaccines for Pig Market The global market for Foot and Mouth Disease (FMD) vaccines for pigs is projected to reach approximately $1.2 billion in 2024, with a significant growth trajectory anticipated through the next decade. By 2034, the market value is expected to rise to about $2.3 billion, reflecting a robust Compound Annual Growth Rate (CAGR) of 6.9% from 2025 to 2034. Flu RNA Vaccines Market The global market for flu RNA vaccines is valued at approximately $2.5 billion, reflecting a growing demand for innovative vaccination solutions amid rising flu cases and the ongoing need for enhanced public health measures. Projections indicate that the market will expand to around $6 billion by 2034, with a Compound Annual Growth Rate (CAGR) of 9.1% over the forecast period from 2025 to 2034. Pediatric Vaccines Market The global pediatric vaccines market is valued at approximately $40 billion, driven by increasing immunization rates and the growing incidence of infectious diseases among children. With advancements in vaccine technologies and rising awareness of preventive healthcare, the market is projected to reach around $70 billion by 2034, marking substantial growth. Shingles Vaccine Market The global shingles vaccine market is valued at approximately $5.1 billion, driven by increasing awareness of shingles and rising vaccination rates among older populations. The market is projected to grow significantly, reaching an estimated value of $10 billion by 2034, with a Compound Annual Growth Rate (CAGR) of 7.1% from 2025 to 2034. U.S. Meningococcal Vaccines Market The U.S. meningococcal vaccines market is valued at approximately $1.5 billion, reflecting a robust demand driven by increasing awareness of meningococcal disease and vaccination initiatives. The market is projected to grow at a CAGR of 6.2%, reaching an estimated $2.7 billion by 2034. This growth trajectory is propelled by several factors, including expanded recommendations for vaccination among adolescents and young adults, and the ongoing efforts to enhance vaccine accessibility and education. Rna Based Therapeutics Market The RNA-based therapeutics market is projected to reach a value of approximately $7.3 billion in 2024, driven by advancements in mRNA technology and increasing investments in gene therapies. The market is expected to expand significantly with a projected value of around $19.6 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of 10.4% during the forecast period from 2025 to 2034. U.S. Vaccine Technologies Market The U.S. vaccine technology market is valued at approximately $70 billion, buoyed by increasing demand for innovative vaccines and heightened awareness of public health needs. The market is projected to grow significantly, with an estimated value reaching $110 billion by 2034, reflecting a robust growth trajectory. Chikungunya Vaccine Future Trends and Market The global chikungunya vaccine market is projected to hold a value of approximately $2.5 billion in 2024. Given the increasing incidence of chikungunya virus infections and the growing awareness regarding preventative healthcare measures, the market is expected to reach around $5.6 billion by 2034. This outlook suggests a robust Compound Annual Growth Rate (CAGR) of 8.5% during the forecast period from 2025 to 2034. Innovations in Vaccine Technologies Market The global vaccine technologies market is projected to reach a value of approximately $65 billion in 2024, with expectations to grow to about $110 billion by 2034. This trajectory represents a compound annual growth rate (CAGR) of around 5.3% during the forecast period from 2025 to 2034. Dendritic Cell Therapy Vaccine Market The dendritic cell therapy vaccine market is valued at approximately $1.2 billion, reflecting a robust interest in innovative immunotherapy solutions. The market is projected to reach around $3.4 billion by 2034, indicating a substantial growth trajectory driven by advancements in personalized medicine and an increasing prevalence of cancer worldwide. Gammaretroviral Vector Market The gammaretroviral vector market is anticipated to reach approximately $1.2 billion in 2024, driven by advancements in gene therapies and increasing applications in biomedical research. The market is projected to grow significantly, with an estimated compound annual growth rate (CAGR) of 8.5% from 2025 to 2034, ultimately reaching around $2.7 billion by the end of this forecast period. Multi Use Bioreactor Market The global multi-use bioreactor market is valued at approximately $3.2 billion, reflecting significant growth driven by advances in biopharmaceutical manufacturing and increased demand for personalized medicine. The projected market value for 2025-2034 is estimated to reach $6.5 billion, highlighting the sector's robust expansion. Medical Refrigerated Market The global medical refrigerated market is valued at approximately $6.5 billion in 2024, with projections indicating a potential increase to around $10 billion by 2034. This growth reflects a robust Compound Annual Growth Rate (CAGR) of approximately 4.5% during the forecast period from 2025 to 2034. Needle for Disposable Injection Pen Market The disposable injection pen market is valued at approximately $4.5 billion in 2024, with expectations to grow significantly over the next decade, reaching an estimated $9 billion by 2034. This growth reflects a Compound Annual Growth Rate (CAGR) of around 7.5% during the forecast period from 2025 to 2034. Meningitis B Vaccine Market The global market for Meningitis B vaccines is valued at approximately $1.1 billion. Projections indicate robust growth, with the market expected to reach $2.4 billion by 2034, driven by increasing awareness of preventive healthcare and advancements in vaccine technology. This represents a Compound Annual Growth Rate (CAGR) of around 8.2% from 2025 to 2034. Human Papillomavirus Vaccine Types 16 18 Market The global market for Human Papillomavirus (HPV) vaccines, particularly those aimed at preventing types 16 and 18, is valued at approximately $3 billion. The market is projected to reach around $5 billion by 2034, reflecting heightened awareness of HPV-related health risks and increased vaccination initiatives worldwide. CONTACT: Irfan Tamboli (Head of Sales) Phone: + 1704 266 3234 Email: sales@ in to access your portfolio

A Nearly 90-Year-Old Chinatown Restaurant Has Expanded
A Nearly 90-Year-Old Chinatown Restaurant Has Expanded

Eater

time37 minutes ago

  • Eater

A Nearly 90-Year-Old Chinatown Restaurant Has Expanded

Wo Hop, which first opened in Chinatown in 1938 and has remained a presence in the neighborhood, has expanded — the first extension in its nearly 90 years in operation. The longtime downstairs basement restaurant has added an entirely new restaurant storefront at street level, with a sleek look that brings the restaurant into a new era. According to neighborhood group Welcome to Chinatown, which advocates for local businesses, the reason for the additional storefront wasn't just about more seating: It 'answers a practical need' to make the subterranean restaurant more accessible to its 'longtime patrons, now in their 50s, 60s, and older, to continue dining at Wo Hop without climbing a steep staircase,' a spokesperson says. But the original location has long served its purpose. 'Perhaps its hidden location helped it resist the changing fashions of Chinatown above, as most chop suey houses vanished by the 1960s,' according to a Welcome to Chinatown release. When the upstairs tenant vacated, the team took over for a dual 17 Mott Street venture. The new space is a collaboration with David Leung, the second-generation owner of Wo Hop, and T.K. Justin Ng, a Chinatown-born architect (who also designed Welcome to Chinatown's office hub). Wo Hop is not to be confused with Wo Hop Next Door, also on Mott Street, which has nuances in its distinct ownership tree and a slightly different menu. It's also often considered the more touristy one; in an interview with Resy, Joanne Kwong, Pearl River Mart president, said: 'Don't trust anyone who says they like both.' The rivalry continues. Wo Hop has weathered a lot: most recently, during COVID, when Chinatown in particular was affected by xenophobia and decreased foot traffic. And now, even as the neighborhood has sprung back to life, its tenure has become all the more notable in the face of encroaching gentrification. An investment in an expansion is an investment in keeping Chinatown alive.

The Alibi was the desert's hottest music venue. Who killed it?
The Alibi was the desert's hottest music venue. Who killed it?

Los Angeles Times

time43 minutes ago

  • Los Angeles Times

The Alibi was the desert's hottest music venue. Who killed it?

Back in the worst pandemic days of 2020, Elizabeth Garo and Melanie Tusquellas were terrified they would lose their nightclub. The co-owners of the Alibi — an independent music venue with space for up to 300 people in downtown Palm Springs — opened in late 2019, just before COVID-19 shut down the live music scene. Garo was a former booker for the Regent, Echo and Echoplex in L.A. (She also opened Stories Books in Echo Park.) Tusquellas was a hospitality veteran behind Los Feliz's El Chavo and Silver Lake's historic Edendale restaurant. The two said they had invested hundreds of thousands into renovating and opening the Alibi. 'It's difficult to run a small independent venue any time, and during COVID it was particularly hard,' Garo recalled in an interview. 'A lot of them didn't make it.' Garo heard that Marc Geiger, then a WME music executive she had known and worked with for decades, and former WME board member John Fogelman had founded Save Live, a company investing in independent venues to help them survive the pandemic. When Save Live offered to buy 51% of the Alibi and let the co-founders continue to run it, the deal 'felt like such a relief,' Garo said. 'It felt like a lifeline, like, 'Hey, we're gonna make it.'' Instead, Garo and Tusquellas claim in a 2023 lawsuit and an interview with The Times that the partnership ruined them. Their lawsuit, which seeks compensatory damages, alleges that Geiger and Fogelman negotiated the deal in bad faith, forcing them out of the company's operations soon after the purchase. After briefly reopening in 2022, the club permanently closed later that year. A trial is set for August. Attorneys for Save Live, which has since rebranded as Gate 52, declined to comment when reached by email. In a cross-complaint to the suit, Geiger and Fogelman say Save Live 'bent over backwards to try to resolve the parties' differences' and call Garo and Tusquellas' claims 'salacious — and utterly false — allegations of misogyny and bad faith.' The suit raises questions about the future of local indie music venues like the Alibi and about Save Live's intentions. Does the firm rescue troubled venues or capitalize on their financial vulnerability? Gate 52 now owns 13 music venues across the country, including Electric City in Buffalo, N.Y., the Eagles Ballroom in Milwaukee and the Criterion in Oklahoma City. In California, the firm owns the Fremont Theater in San Luis Obispo and the Golden State Theatre in Monterey, and collaborates with dozens more 'network venues' across the country. The firm is a far cry from giants like Live Nation or AEG. But as a well-capitalized operation that has acquired majority stakes in struggling small venues, it has become a significant player in secondary markets. The two-story, Spanish colonial-style building that would become the Alibi first opened as a switchboard hub for the GE Telephone Co. in the 1920s. Later, it became Georgie's Alibi Azul, a popular gay bar and restaurant. In 2018, Garo and Tusquellas, both wisecracking Gen X veterans of L.A. nightlife, were looking for 'a swan song' for their careers, as Tusquellas described it. Garo, one of the most influential talent bookers in L.A. for decades, had been laid off from Live Nation after the mega-promoter bought local promoter Spaceland Presents. After touring the Alibi, Garo and Tusquellas saw potential for a venue like the ones they'd built in L.A., a place to book local and global artists in a creatively adapted old building. 'We were surprised by how chic and international Palm Springs was becoming,' Tusquellas added. 'Growing up in L.A., when we went to Palm Springs as kids, it was like God's waiting room. But we were quite surprised by this scene with all these local musicians but no venues to play at.' Alibi soft-launched with packed Pride events in fall 2019 (to avoid the summer heat), and formally opened in October. With its glazed-tile outdoor bar and emerald-hued mood lighting, the venue was a chic standout in desert nightlife. 'We had everything from 'Dynasty' theme parties to Modernism Week events,' Tusquellas said. 'We had a goth night. There had never been a place to go for them in Palm Springs and they came out of the woodwork.' Local musicians hoped the venue would be transformative for their scene. 'Alibi was the first place where we got a taste of the real deal,' said Spencer Stange of the band Host Family, which booked a monthly night of experimental music at Alibi. 'It was the only venue I knew there that was legitimate and professional. Good bands played there and you could do a real sound check. They were so hospitable, it felt like a home base.' Louise Minnick, a local promoter with Lesbo Expo, said Alibi was an important venue for queer women in the desert. 'Liz and Melanie went out of their way to make our events special,' Minnick said. 'They offered their patio for women to have first access to watch Pride, which meant a lot to me.' Five months later, the pandemic annihilated those plans. Garo and Tusquellas said their company, 369 Palm Inc., was too new to access the federal patchwork of Paycheck Protection Program loans. They eventually got a grant from the National Independent Venue Assn., but it was for only $20,000. According to a slide deck cited in Save Live's cross-complaint, the venue had $250,000 in outstanding bills from the shutdown. 'We used all our savings to pay the rent,' Tusquellas added. 'We're entrepreneurs who are not funded by big people, so we had to pay the $15,000 a month rent ourselves for a year and a half. It was really hard.' Meanwhile, Save Live launched in 2020 with $135 million raised from venture capital firms and a clear mission: to buy majority stakes in small clubs. 'Save Live's business model was to invest in local, independent, 'mom and pop' live music venues, providing critically needed financial relief and funds to renovate dated facilities to bring them back stronger than ever before,' the company says in its cross-complaint. Save Live's founders were well-known in L.A. entertainment. Geiger co-founded the Lollapalooza festival and led WME's music division from 2003 until 2020. Fogelman was the former head of motion pictures at William Morris Agency and a founding board member when it merged with Endeavor to become WME. The Alibi was one of Save Live's first venue deals. 'Being able to partner with Save Live is a dream come true,' Garo said in a 2021 announcement. The deal let the two owners 'stay true to our roots knowing we have their full support. … It doesn't hurt that we've known some of the people at Save Live for years — we all came up through the business together.' 'I didn't know Marc at all, but he was very charming,' Tusquellas said. 'He and Fogelman were titans of the industry. We felt that we were in very good hands. We knew what we were doing, and they knew that.' According to the suit and cross-complaint, Garo and Tusquellas' company, 369 Palm Inc. (with partner David Gold), agreed to sell 51% of their ownership of the Alibi's business to Save Live for $400,000. The Alibi's business would be co-owned under a new company, Alibi Venue Operations LLC. Garo and Tusquellas say in their suit that, under this agreement, the pair and Geiger 'would have decision-making authority over the day-to-day operations.' Garo and Tusquellas claim in their suit that 369 Palm 'retained 100% ownership of [the Alibi's] ABC liquor license' and would continue to manage the venue's bar. Save Live agreed to provide $565,000 for renovations and expenses, according to Save Live's cross-complaint. Garo and Tusquellas' suit claims that Save Live had 'hatched a plan to exploit the weakness in the independent live music industry to try, by means of deception and then intimidation, to acquire The Alibi and its business without paying a fair price.' Scott Timberlake, the Alibi building's landlord, said he had a friendly relationship with Garo and Tusquellas. But once Save Live got involved, he said, 'I was really surprised by Save Live's ego and entitlement. When I asked to see their financial statements before taking over the lease, they lectured me about 'Don't you know who we are?'' Garo and Tusquellas say in their suit that, when the venue reopened on April 1, 2022, 'SL Alibi acted as if it were the sole owner.' They claim in their suit that Geiger and Fogelman contracted with an outside ticketing company, Tixr, without Garo's consent, and that Save Live didn't sufficiently fund day-to-day operations. Garo and Tusquellas claim in their suit that Save Live switched to its own accountant for bookkeeping and backed out of a plan to hire a general manager. In its cross-complaint, Save Live says that 'contrary to the claims in their lawsuit, Save Live did not try to take over the Venue.' Save Live says 'Tusquellas and Garo had gone significantly over the pre-opening budget, resulting in … an operating budget shortfall.' According to Save Live's cross-complaint, private investigators discovered 'a separate, undisclosed cash register used only for cash transactions … there was no record, whatsoever, of any such sales.' The cross-complaint alleges that Tusquellas 'embezzled most of (if not all) of the cash sale proceeds.' Tusquellas denied the embezzlement claims, saying all sales, including cash, were accounted for and reported as income. Save Live says in its cross-complaint that both parties 'always understood and intended for 369 to transfer' the venue's valuable liquor license, and called Garo and Tusquellas' refusal to do so 'a ruse to get Save Live's money.' Garo and Tusquellas said they never sold, or intended to sell, the venue's liquor license. 'That may have been part of Save Live's secret plan,' said 369 Palm's lawyer, David Sergenian. 'But that was never agreed to.' On July 13, 2022, Garo and Tusquellas' lawsuit says 'Geiger and Fogelman called a meeting of the Board … as a pretense to ambush Tusquellas and Garo with false accusations. Geiger and Fogelman…falsely accus[ed] Tusquellas of embezzling funds from the company to enrich herself.' 'Fogelman aggressively threw a chair to the ground, as he raged,' the suit says. 'Tusquellas and Garo were appalled by Fogelman's shocking behavior and scared for their future, as he was threatening to ruin the business by shutting down The Alibi.' Garo and Tusquellas' suit claims Geiger and Fogelman ordered the venue shut down and that Garo and Tusquellas be removed from operations with their salaries cut off. The bar staff would be fired and 369 Palm's concessionaire agreement canceled, according to the suit. The Alibi closed on July 25, 2022. It never reopened. The situation at the Alibi echoes the tumult surrounding the ownership of the beloved Pioneertown venue Pappy & Harriet's. Starting in 2021, Knitting Factory Chief Executive Morgan Margolis and partners Stephen Hendel and John Chapman battled the venue's co-partners, Joseph Moresco and Lisa Elin, about who controlled the operations at the rustic venue, where acts as big as Paul McCartney and Robert Plant have played in addition to hardscrabble desert locals. Margolis prevailed in late 2024. Meanwhile, the new Acrisure Arena, built by mega-manager Irving Azoff and former AEG President Tim Leiweke, attracts A-list pop, rock and Latin acts to Palm Springs. The nearby Yaamava' resort has spent millions on top talent. 'It's great to have an influx of money and big artists at venues like Acrisure Arena that helps the Valley feel bigger. But losing small venues is detrimental and cuts away at the uniqueness of the experiences people have here,' said Kristen Dolan, executive director of the California Desert Arts Council, a nonprofit group advocating for cultural development in the Coachella Valley. 'Places like Alibi have a bigger impact than people think. The workforce here is largely in hospitality, and clubs like the Alibi are important places to start out,' Dolan said. 'People were really upset when the Alibi closed, and it was heartbreaking for artists cultivating their community. The economy here is unstable right now and I hope we don't lose more small venues like it.' The post-pandemic future for such independent live venues is unsettled. Nonprofits like NIVA were effective advocates for legislation (like the $16.25 billion Shuttered Venue Operators Grant, a federal program that gave money to struggling venues) and fundraising, and concert attendance boomed once venues reopened. But inflation, reduced tourism and a volatile economy threaten to keep fans home. 'What word describes our situation right now? I would offer that one word is 'unknown,' NIVA's executive director Stephen Parker said at the group's 2024 conference. 'Forty years ago, independent stages were the norm, now multinational, publicly traded conglomerates are. Everyone in this room knows that competition is a misnomer and the increasing lack of it is, perhaps, our greatest threat.' Meanwhile, Garo and Tusquellas have returned to L.A., picking up the pieces at an unexpectedly late phase of their careers. Garo will book shows at a new independent Yucca Valley venue, Mojave Gold. Building owner Timberlake said that after months of fighting with Save Live over the venue's debts, he accepted a settlement, and a new restaurant tenant has moved into the Alibi. 'I didn't have the financial capability of fighting someone like Save Live,' he said. 'It was just so unnecessarily negative.' No matter how the August trial ends, Garo and Tusquellas are facing the same headwinds as the rest of the live industry. Only now, they are truly on their own. 'I have lots of ideas,' Garo said. 'But that's all kind of locked up until we get this resolved. I don't want this to be my final chapter.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store